Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

4.655 +0.025 (+0.54%)
Streaming Delayed Price Updated: 11:11 AM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Avalo Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics to Present at Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces Participation in September Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
From Avalo Therapeutics
Via GlobeNewswire
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports 2023 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
From Avalo Therapeutics
Via GlobeNewswire
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
From Avalo Therapeutics
Via GlobeNewswire
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics
NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks... 
Via TheNewswire.com
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
From Avalo Therapeutics
Via GlobeNewswire
Avalo Enters into Agreement to Divest AVTX-800 Series
From Avalo Therapeutics
Via GlobeNewswire
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Avalo Therapeutics
Via GlobeNewswire
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Avalo to Participate in SVB Securities Therapeutics Forum
From Avalo Therapeutics
Via GlobeNewswire
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
From Avalo Therapeutics
Via GlobeNewswire
Avalo to Present at the Jefferies Healthcare Conference
From Avalo Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.